Education
About Us
Working with TipRanks
Follow Us
Scinai Immunotherapeutics (SCNI)
NASDAQ:SCNI
SCNI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.31 - $6.18
Previous CloseN/A
Volume8.73K
Average Volume (3M)250.53K
Market Cap
$1.21M
Enterprise Value$8.60M
Total Cash (Recent Filing)$1.03M
Total Debt (Recent Filing)$1.23M
Price to Earnings (P/E)0.3
Beta1.24
Next Earnings
Nov 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.72
Shares Outstanding933,679
10 Day Avg. Volume100,304
30 Day Avg. Volume250,525
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap7.10
Enterprise Value/Revenue19.02
Enterprise Value/Gross Profit-20.81
Enterprise Value/Ebitda1.45
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Scinai Immunotherapeutics News
SCNI FAQ
What was Scinai Immunotherapeutics’s price range in the past 12 months?
Scinai Immunotherapeutics lowest stock price was $1.31 and its highest was $6.18 in the past 12 months.
What is Scinai Immunotherapeutics’s market cap?
Scinai Immunotherapeutics’s market cap is $1.21M.
When is Scinai Immunotherapeutics’s upcoming earnings report date?
Scinai Immunotherapeutics’s upcoming earnings report date is Nov 26, 2025 which is in 61 days.
How were Scinai Immunotherapeutics’s earnings last quarter?
Scinai Immunotherapeutics released its earnings results on Aug 21, 2025. The company reported -$3.716 earnings per share for the quarter, missing the consensus estimate of N/A by -$3.716.
Is Scinai Immunotherapeutics overvalued?
According to Wall Street analysts Scinai Immunotherapeutics’s price is currently Overvalued.
Does Scinai Immunotherapeutics pay dividends?
Scinai Immunotherapeutics does not currently pay dividends.
What is Scinai Immunotherapeutics’s EPS estimate?
Scinai Immunotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scinai Immunotherapeutics have?
Scinai Immunotherapeutics has 933,679 shares outstanding.
What happened to Scinai Immunotherapeutics’s price movement after its last earnings report?
Scinai Immunotherapeutics reported an EPS of -$3.716 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 12.338%.
Which hedge fund is a major shareholder of Scinai Immunotherapeutics?
Currently, no hedge funds are holding shares in SCNI
Company Description
Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Technical Analysis
TNF Pharmaceuticals
―
Entero Therapeutics
―
Protagenic Therapeutics
―
ZyVersa Therapeutics
―
PMGC Holdings
―
Ownership Overview
7.40%
Insiders
0.02% Mutual Funds
<0.01% Other Institutional Investors
92.60% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---